Why Drugmaker Eli Lilly Is Partnering With ChatGPT Maker OpenAI [Video]

Eli Lilly (LLY) said it is partnering with ChatGPT maker OpenAI to use artificial intelligence (AI) to develop new treatments to combat drug-resistant diseases.

The companies said Tuesday that they will work together to create “novel antimicrobials” to fight drug-resistant pathogens, calling antimicrobial resistance (AMR) one of the “top public health and development threats across the global health landscape.”

“Our collaboration with OpenAI represents a groundbreaking step forward in the fight against the growing but overlooked threat of antimicrobial resistance,” Eli Lilly Chief Information and Digital Officer Diogo Rau said in a statement.

“Generative AI opens a new opportunity to accelerate the discovery of novel antimicrobials and the development of custom, purpose-built technologies in the battle against drug-resistant pathogens. This partnership underscores our commitment to addressing significant health challenges experienced by people around the world,” Rau said.

Tuesday’s announcement didn’t discuss financial terms. Eli Lilly in 2020 committed $100 million to developing two to four new antibiotics by …